

- [57] Cholera, 2004. *Wkly Epidemiol Rec* 2005;80:261-8.
- [58] Sack DA, Islam S, Brown KH, Islam A, Kabir AK, Chowdhury AM, et al. Oral therapy in children with cholera: a comparison of sucrose and glucose electrolyte solutions. *J Pediatr* 1980;96:20-5.
- [59] Tacket CO, Sack DA. Cholera vaccines. In: Plotkin SA, Orenstein WA, Offit PA, editors. *Vaccines* 5th ed: Saunders-Elsevier, 2008: 127-38.
- [60] Sack DA, Sack RB, Nair GB, Siddique AK. Cholera. *Lancet* 2004;363:223-33.
- [61] Koelle K, Rodo X, Pascual M, Yunus M, Mostafa G. Refractory periods and climate forcing in cholera dynamics. *Nature* 2005;436:696-700.
- [62] Faruque SM, Naser IB, Islam MJ, Faruque AS, Ghosh AN, Nair GB, et al. Seasonal epidemics of cholera inversely correlate with the prevalence of environmental cholera phages. *Proc Natl Acad Sci U S A* 2005;102:1702-7.
- [63] Steinberg EB, Greene KD, Bopp CA, Cameron DN, Wells JG, Mintz ED. Cholera in the United States, 1995-2000: trends at the end of the twentieth century. *J Infect Dis* 2001;184:799-802.
- [64] World, Health, Organization. Cholera, 2006. *Wkly Epidemiol Rec* 2007;82:273-84.
- [65] Zuckerman JN, Rombo L, Fisch A. The true burden and risk of cholera: implications for prevention and control. *Lancet Infect Dis* 2007;7:521-30.
- [66] Pancharoen C, Niwattanakajana N, Mekmullica J, Chongsrisawat V. Hospital-based epidemiology of childhood cholera: a 6-year review in a university hospital in Bangkok, Thailand. *J Med Assoc Thai* 2004;87 Suppl 2:S59-61.
- [67] WHO. Cholera unveiled. Global Task Force on Cholera Control [http://whqlibdoc.who.int/hq/2003/WHO\\_CDS\\_CPE\\_ZFK\\_2003.3pdf](http://whqlibdoc.who.int/hq/2003/WHO_CDS_CPE_ZFK_2003.3pdf).
- [68] Sanchez J, Holmgren J. Virulence factors, pathogenesis and vaccine protection in cholera and ETEC diarrhea. *Curr Opin Immunol* 2005;17:388-98.
- [69] National, Travel, Health, Network, and, Centre. Travellers. Travel health information sheets. Cholera. <http://www.nathnac.org/travel/factsheets/cholera.htm>. [cited; Available from:
- [70] Lonnoth I, Holmgren J. Subunit structure of cholera toxin. *J Gen Microbiol* 1973;76:417-27.
- [71] Ryan ET, Calderwood SB. Cholera vaccines. *Clin Infect Dis* 2000;31:561-5.
- [72] Ivanoff B, Chaignat CL. [Anticholera vaccines and vaccination]. *Bull Soc Pathol Exot* 2002;95:355-8.
- [73] Peltola H, Siitonen A, Kyronseppa H, Simula I, Mattila L, Oksanen P, et al. Prevention of travellers' diarrhoea by oral B-subunit/whole-cell cholera vaccine. *Lancet* 1991;338:1285-9.
- [74] Lopez-Gigosos R, Garcia-Fortea P, Reina-Dona E, Plaza-Martin E. Effectiveness in prevention of travellers' diarrhoea by an oral cholera vaccine WC/rBS. *Travel Med Infect Dis* 2007;5:380-4.
- [75] Clemens JD, Sack DA, Harris JR, Van Loon F, Chakraborty J, Ahmed F, et al. Field trial of oral cholera vaccines in Bangladesh: results from three-year follow-up. *Lancet* 1990;335:270-3.
- [76] van Loon FP, Clemens JD, Chakraborty J, Rao MR, Kay BA, Sack DA, et al. Field trial of inactivated oral cholera vaccines in Bangladesh: results from 5 years of follow-up. *Vaccine* 1996;14:162-6.
- [77] Legros D, Paquet C, Perea W, Marty I, Mugisha NK, Royer H, et al. Mass vaccination with a two-dose oral cholera vaccine in a refugee camp. *Bull World Health Organ* 1999;77:837-42.
- [78] Lucas ME, Deen JL, von Seidlein L, Wang XY, Ampuero J, Puri M, et al. Effectiveness of mass oral cholera vaccination in Beira, Mozambique. *N Engl J Med* 2005;352:757-67.
- [79] Ali M, Emch M, Yunus M, Sack D, Lopez AL, Holmgren J, et al. Vaccine Protection of Bangladeshi infants and young children against cholera: implications for vaccine deployment and person-to-person transmission. *Pediatr Infect Dis J* 2008;27:33-7.
- [80] Trach DD, Cam PD, Ke NT, Rao MR, Dinh D, Hang PV, et al. Investigations into the safety and immunogenicity of a killed oral cholera vaccine developed in Viet Nam. *Bull World Health Organ* 2002;80:2-8.
- [81] Trach DD, Clemens JD, Ke NT, Thuy HT, Son ND, Canh DG, et al. Field trial of a locally produced, killed, oral cholera vaccine in Vietnam. *Lancet* 1997;349:231-5.

- [82] Vu DT, Hossain MM, Nguyen DS, Nguyen TH, Rao MR, Do GC, et al. Coverage and costs of mass immunization of an oral cholera vaccine in Vietnam. *J Health Popul Nutr* 2003;21:304-8.
- [83] WHO. Initiative for Vaccine Research, WHO, Proceedings of the 7th Global Vaccine Research Forum. Bangkok; 2006.
- [84] Tacket CO, Cohen MB, Wasserman SS, Losonsky G, Livio S, Kotloff K, et al. Randomized, double-blind, placebo-controlled, multicentered trial of the efficacy of a single dose of live oral cholera vaccine CVD 103-HgR in preventing cholera following challenge with *Vibrio cholerae* O1 El tor inaba three months after vaccination. *Infect Immun* 1999;67:6341-5.
- [85] Richie EE, Punjabi NH, Sidharta YY, Peetosutan KK, Sukandar MM, Wasserman SS, et al. Efficacy trial of single-dose live oral cholera vaccine CVD 103-HgR in North Jakarta, Indonesia, a cholera-endemic area. *Vaccine* 2000;18:2399-410.
- [86] Calain P, Chaine JP, Johnson E, Hawley ML, O'Leary MJ, Oshitani H, et al. Can oral cholera vaccination play a role in controlling a cholera outbreak? *Vaccine* 2004;22:2444-51.
- [87] Garcia L, Jidy MD, Garcia H, Rodriguez BL, Fernandez R, Ano G, et al. The vaccine candidate *Vibrio cholerae* 638 is protective against cholera in healthy volunteers. *Infect Immun* 2005;73:3018-24.
- [88] Cohen MB, Giannella RA, Bean J, Taylor DN, Parker S, Hoepfer A, et al. Randomized, controlled human challenge study of the safety, immunogenicity, and protective efficacy of a single dose of Peru-15, a live attenuated oral cholera vaccine. *Infect Immun* 2002;70:1965-70.
- [89] Qadri F, Chowdhury MI, Faruque SM, Salam MA, Ahmed T, Begum YA, et al. Randomized, controlled study of the safety and immunogenicity of Peru-15, a live attenuated oral vaccine candidate for cholera, in adult volunteers in Bangladesh. *J Infect Dis* 2005;192:573-9.
- [90] Roland KL, Cloninger C, Kochi SK, Thomas LJ, Tinge SA, Rouskey C, et al. Construction and preclinical evaluation of recombinant Peru-15 expressing high levels of the cholera toxin B subunit as a vaccine against enterotoxigenic *Escherichia coli*. *Vaccine* 2007;25:8574-84.
- [91] Ledon T, Valle E, Valmaseda T, Cedre B, Campos J, Rodriguez BL, et al. Construction and characterisation of O139 cholera vaccine candidates. *Vaccine* 2003;21:1282-91.
- [92] Nochi T, Takagi H, Yuki Y, Yang L, Masumura T, Mejima M, et al. Rice-based mucosal vaccine as a global strategy for cold-chain- and needle-free vaccination. *Proc Natl Acad Sci U S A* 2007;104:10986-91.
- [93] Perez JL, Acevedo R, Callico A, Fernandez Y, Cedre B, Ano G, et al. A proteoliposome based formulation administered by the nasal route produces vibriocidal antibodies against El Tor Ogawa *Vibrio cholerae* O1 in BALB/c mice. *Vaccine* 2009;27:205-12.
- [94] Ryan ET, Calderwood SB, Qadri F. Live attenuated oral cholera vaccines. *Expert Rev Vaccines* 2006;5:483-94.